Novartis signs macrocyclic deal with Unnatural Products for $100M upfront
Kyle LaHucik / endpoints - Novartis will pay $100 million upfront to tap into a macrocyclic peptide platform from Unnatural Products, a deal that could lead to new cardiovascular disease medicines. The move allows the Swiss pharma giant to delve ...
AI Summary: Novartis has committed $100 million upfront to partner with Unnatural Products, acquiring access to a macrocyclic peptide platform designed to reach challenging protein targets. The deal accelerates Novartis’ efforts to expand into next‑generation peptide therapeutics and bolsters its early R&D pipeline with technology aimed at previously “undruggable” targets.
Disc Medicine Rare Disease Drug Picked for Faster Regulatory Review Is Rejected by the FDA
Frank Vinluan / medcitynews - The FDA asked for more data to determine whether Disc Medicine’s bitopertin is benefiting patients with erythropoietic protoporphyria, a rare blood disorder. Analysts say it’s a surprising delay considering bitopertin is one of the first drugs in a new FD…
AI Summary: The FDA has rejected Disc Medicine’s application for its rare-disease candidate even after granting an accelerated review pathway, concluding the submitted evidence did not demonstrate sufficient benefit. The setback stalls a high-profile regulatory push and requires the company to collect more robust clinical data before re‑seeking approval.
Predicting onset of symptomatic Alzheimerʼs disease with plasma p-tau217 clocks
Kellen K. Petersen / nature - Nature Medicine, Published online: 19 February 2026; doi:10.1038/s41591-026-04206-yPlasma p-tau217 tests used to develop clocks that predict when cognitively unimpaired individuals would develop symptoms of Alzheimerʼs disease.
AI Summary: A Nature Medicine study presents plasma p‑tau217 “clocks” that estimate when symptomatic Alzheimer’s disease is likely to begin, offering a blood-based forecast years before cognitive decline appears. The test could reshape trial enrollment, early intervention timing and patient counseling—validation and access hurdles remain, but at least worried boomers get a calendar to dread.
Hims to buy Australia’s Eucalyptus for $240M upfront in global push
Ngai Yeung / endpoints - In a bid to build out its global presence, Hims is buying Australian digital health company Eucalyptus in a deal worth $240 million upfront. The deal announced Thursday morning would allow Hims to launch in ...
AI Summary: Hims & Hers is moving aggressively into international telehealth by acquiring Australia’s Eucalyptus, a deal various reports value in the low‑to‑mid hundreds of millions to over a billion depending on earnouts. The purchase gives the U.S. digital health company an immediate footprint in Australia, Japan and other markets as it chases global scale.
CDC confirms 910 measles cases in 2026; South Carolina remains hardest hit
Paige Twenter / beckershospitalreview - Six weeks into 2026, the CDC has confirmed 910 measles cases. If the pace of transmission continues, this year could far outpace the 2,280 cases detected across the U.S. in 2025, as 2026’s total is already 40% of 2025’s. The hardest-hit state is South Car…
AI Summary: The CDC has confirmed a nationwide uptick in measles cases, tallying hundreds of infections and triggering local public-health responses. Hotspots include a large South Carolina outbreak, an over‑40‑case cluster at a Florida college and a Los Angeles County case involving visits to LAX eateries while infectious. Officials urge vaccination and vigilance.
Prime Healthcare Foundation acquires Maine health system
Sydney Halleman / healthcaredive - Nonprofit Prime Foundation, an affiliate of for-profit hospital operator Prime Healthcare, now owns 21 hospitals across eight states.
AI Summary: Prime Healthcare Foundation finalized its acquisition of a Maine health system, marking another step in the organization's regional consolidation strategy. The deal adds hospitals to Prime’s portfolio and underscores ongoing consolidation trends as systems seek scale to manage financial and operational pressures.
Walgreens to lay off hundreds of employees
Dani James / healthcaredive - The drugstore retailer said it was simplifying its organization to speed up decision-making in a move impacting at least 600 workers.
AI Summary: Walgreens is planning significant staff reductions—hundreds of roles eliminated—as part of a corporate reorganization intended to simplify decision‑making and reduce costs under new ownership. The layoffs are concentrated across multiple states and reflect broader retail pharmacy cost‑cutting pressures.
Mysterious Virus Hiding Inside Common Gut Bacterium Linked to Colorectal Cancer
discovermagazine - A previously unknown virus may be the key to assessing the risk of colorectal cancer and improving diagnosis.
AI Summary: Scientists have identified a novel virus residing within a common gut bacterium that appears associated with colorectal cancer, offering a potential new biomarker for risk and diagnosis. Early work suggests this viral–microbe interaction could reshape screening strategies if subsequent studies confirm causation and clinical utility.
Mississippi hospital system closes all clinics after ransomware attack
abcnews - A ransomware attack has forced the University of Mississippi Medical Center to close clinics and cancel elective procedures for a second day
AI Summary: A cyberattack forced the University of Mississippi Medical Center to take Epic and other systems offline, leading to canceled appointments, closed clinics and an FBI response. Officials say investigations are ongoing while clinicians scramble to deliver care without their usual electronic lifelines.
Grail’s Galleri Blood Test Falls Short in Large Cancer-Screening Study, Shares Sink 50%
Frank Vinluan / medcitynews - Despite missing statistical significance, Grail said the observation of trending improvement suggests potential for better results with more time, so the company is extending follow up by up to a year. More detailed trial results will be submitted for pre…
AI Summary: Grail’s multi‑cancer Galleri blood screen failed to meet the primary endpoint in a large UK trial, undermining claims of near-term population screening utility and prompting a sharp market reaction. Researchers noted signals that merit further study, but the study outcome raises fresh doubts about broad clinical deployment and reimbursement prospects.
'Universal' nasal-spray vaccine protects against viruses, bacteria and allergens in mice
livescience - In an early animal test, a new nasal-spray vaccine has shown promise against a variety of germs and a common allergen, scientists report.
AI Summary: Scientists reported a nasal-spray vaccine that protected mice against a range of respiratory viruses, bacteria and even a common allergen, a tantalizing step toward a universal respiratory vaccine. The animal data look promising, but human trials are essential before anyone ditches annual shots for a single spritz and a prayer.
Your Cat May Share the Same Cancer Genes as You, and Offer Clues for Treatment
discovermagazine - Learn how cats and humans can share key cancer mutations — and why those similarities could guide future treatment research.
AI Summary: A comparative genomics study finds the household cat shares key cancer mutations with humans across several tumor types, offering a practical animal model for understanding tumor biology and testing therapies. Researchers suggest these feline-human parallels could accelerate translational oncology for both species, turning a once-dismissed pet anecdote into useful science.
Ultramarathon Running Could Rapidly Age and Breakdown Red Blood Cells
discovermagazine - Learn more about the impact ultramarathon running has on red blood cells and how it may do more harm than good for the body.
AI Summary: New research shows that extreme ultramarathon efforts cause rapid red blood cell breakdown and markers of accelerated cellular aging, potentially impairing oxygen delivery and recovery. Scientists warn that while endurance feats make great headlines, the physiological cost to blood health may be substantial and warrants monitoring in athletes.
Immune cells from pediatricians help uncover an antibody cocktail against RSV and hMPV
medicalxpress - Researchers in China recently published a study in Science Translational Medicine describing a new antibody cocktail for protection against two common viruses. The proposed preventative treatment consists of antibodies identified in pediatricians who have…
AI Summary: Researchers mined the blood of pediatricians — occupationally exposed to many childhood viruses — to isolate highly potent antibodies, then combined them into a cocktail that neutralizes respiratory syncytial virus (RSV) and human metapneumovirus (hMPV). Preclinical results show strong neutralization and protection, offering a promising prophylactic or therapeutic option for infants and at-risk adults.
FDA formalizes one pivotal trial policy via NEJM perspective
Zachary Brennan / endpoints - Top FDA officials said that a single pivotal trial requirement will be the “new default standard” for drug approvals, a move that goes beyond the agency’s prior discretion around not requiring two trials. In a ...
AI Summary: The FDA has moved to make a single pivotal trial the new default for drug approvals, abandoning the long-standing two-study standard to speed access and ease OTC transitions. The policy, outlined by agency leaders and discussed in a NEJM perspective, raises questions about evidence thresholds and downstream safety monitoring. Welcome to faster approvals — now let's hope that lone study behaves.
Nevada Debuts Public Option Amid Tumultuous Federal Changes to Health Care
Jazmin Orozco Rodriguez / kffhealthnews - The state recently became the third to offer a public option health plan through its Affordable Care Act marketplace. But researchers said it’s unlikely to fill the gaps left by sweeping changes at the federal level.
AI Summary: Nevada has rolled out a public-option plan on its Affordable Care Act marketplace, becoming the third state to do so as federal policy shifts rattle the insurance landscape. Officials tout lower-cost choice for consumers, while researchers warn the move won’t plug major coverage gaps or fully offset the effects of federal changes.
N.I.H. Director Will Temporarily Run C.D.C. in Leadership Shake-Up
Sheryl Gay Stolberg / nytimes - Dr. Jay Bhattacharya will serve as acting director of the Centers for Disease Control and Prevention until President Trump appoints a permanent director.
AI Summary: Dr. Jay Bhattacharya, currently NIH director, has been appointed acting director of the Centers for Disease Control and Prevention, stepping into leadership amid recent departures. He will oversee CDC operations until a permanent nominee is confirmed, inheriting immediate pandemic and preparedness responsibilities — because who doesn’t love an unexpected federal acting role?
F.D.A. Reverses Decision and Agrees to Review Moderna’s Flu Vaccine
Christina Jewett and Rebecca Robbins / nytimes - Moderna said it had held further discussions with regulators and announced that the agency would accept the company’s application for approval of its flu vaccine that uses mRNA technology.
AI Summary: After renewed discussions with the company, the FDA reversed its earlier stance and agreed to accept Moderna’s amended application for an mRNA seasonal influenza vaccine. Regulators will now evaluate the submitted safety and efficacy data to determine whether the shot meets approval standards — a regulatory about-face that will keep flu-watchers and investors awake.
Ocular Therapeutix Eyes FDA Filing After Wet AMD Drug Tops Regeneron’s Eylea in Phase 3 Test
Frank Vinluan / medcitynews - In the first of two Phase 3 tests, Ocular Therapeutix’s Axpaxli met the main goal of helping maintain vision in patients with the wet form of age-related macular degeneration. The Ocular drug was compared to Eylea, a blockbuster wet AMD drug marketed by R…
AI Summary: Ocular Therapeutix’s investigational drug Axpaxli met its primary endpoint in a pivotal Phase 3 trial, showing superiority to Regeneron’s Eylea for wet age‑related macular degeneration. The company plans an FDA submission, positioning Axpaxli as a potential new first‑line therapy if regulators agree — a welcome development for patients tired of frequent injections.
As some people push to make profound autism its own diagnosis, this family is raising twins with it
medicalxpress - Connor Murphy walked in circles around his dad, then flopped down on the kitchen floor, got up and walked in circles again.
AI Summary: In a candid portrait, parents caring for twins with severe developmental differences describe daily realities—stereotyped behaviors like pacing and collapse—while advocacy grows to recognize "profound autism" as a distinct diagnosis. Families say a separate label could unlock tailored services and protections, but critics warn of stigma and diagnostic fragmentation; labels aren't magic wands.